根据美国证券交易委员会的一份文件显示，Natera, Inc.（纳斯达克股票代码：NTRA）的执行董事长Matthew Rabinowitz最近出售了大量公司股票。该公司股票今年以来已上涨超过165%，目前在52周高点附近交易，价格为166.55美元。根据 InvestingPro ...

Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the ...

Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

Children's Health?, one of the largest and most prestigious pediatric health care institutions in the country and the leading pediatric health care system in North Texas, opened its ...

CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Sometimes the most under-hyped sectors are the best places to build very large businesses,” said one venture investor who ...

Natera, Inc.（纳斯达克股票代码：NTRA）的董事Chapman Rowan ...

From M&A and tariffs to new health leaders, here are the top issues for the medtech industry to watch when President-elect ...

The genetic testing market accounted for $ 12,682 million in 2019, and is expected to reach $ 21,260 million by 2027, registering a CAGR of 10.1% from 2020 to 2027. The global genetic testing market ...